Skip to content

LSD: all studies

Page 31 of 282: studies 301 to 310 of 2,815, newest first. Back to the LSD overview

Research

The entropic tongue: Disorganization of natural language under LSD.

Consciousness and Cognition December 8, 2020 Camila Sanz, Carla Pallavicini, Facundo Carrillo et al. 34 citations

Serotonergic psychedelics have been suggested to mirror certain aspects of psychosis, and, more generally, elicit a state of consciousness underpinned by increased entropy of on-going neural activity. We investigated the hypothesis that language produced under the effects of lysergic acid diethylamide (LSD) should exhibit increased entropy and reduced semantic coherence. Computational analysis...

DOI: 10.1016/j.concog.2020.103070 (opens in new tab) LSD Language Effects Speech disorganization Psychedelic neuroscience

Acute Lysergic Acid Diethylamide Does Not Influence Reward-Driven Decision Making of C57BL/6 Mice in the Iowa Gambling Task

Frontiers in Pharmacology December 3, 2020 Lauri Elsilä, Nuppu Korhonen, Petri Hyytiä et al. 13 citations

While interest in psychedelic drugs in the fields of psychiatry and neuroscience has re-emerged in recent last decades, the general understanding of the effects of these drugs remains deficient. In particular, there are gaps in knowledge on executive functions and goal-directed behaviors both in humans and in commonly used animal models. The effects of acute doses of psychedelic lysergic acid...

Re-evaluation of the discriminative stimulus effects of lysergic acid diethylamide with male and female Sprague-Dawley rats

Behavioural Pharmacology December 1, 2020 Keli A. Herr, Lisa E Baker 9 citations

Recent discoveries from clinical trials with psychedelic-assisted therapy have led to a resurgence of interest in the psychopharmacology of lysergic acid diethylamide (LSD). Preclinical drug discrimination is an invaluable tool to investigate the neurochemical mechanisms underlying subjective drug effects. The current study extends previous drug discrimination research by including both sexes....

Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine

Journal of Neuroscience November 30, 2020 Danilo de Gregorio, Argel Aguilar-Valles, Katrin H. Preller et al. 258 citations

A revamped interest in the study of hallucinogens has recently emerged, especially with regard to their potential application in the treatment of psychiatric disorders. In the last decade, a plethora of preclinical and clinical studies have confirmed the efficacy of ketamine in the treatment of depression. More recently, emerging evidence has pointed out the potential therapeutic properties of...

Marginalisation, stigmatisation et abandon du LSD en médecine

November 5, 2020 Z. Dubus

Apres avoir ete l’une des substances pharmacologiques les plus etudiees des annees 1950-1970, le LSD, puissant psychedelique ayant de nombreuses indications therapeutiques, est abandonne par la communaute scientifique internationale au debut des annees 1970. Si des facteurs externes a la medecine ont eu un impact sur le declin de ce medicament, il est egalement necessaire de s’interroger sur...

Identification of LSD Derivatives, 1cP-LSD, MIPLA and 1B-LSD in Illegal Products as Paper Sheet

Yakugaku Zasshi October 31, 2020 Rie Tanaka, Maiko Kawamura, Takashi Hakamatsuka et al. 15 citations

Lysergic acid diethylamide (LSD) is a hallucinogen, synthesized from ergot alkaloid, and controlled as a narcotic in Japan. Recently, LSD derivatives have appeared as designer drugs, all over the world. In previous study, we reported identification and analysis of four LSD derivatives in four paper sheet products. In this study, we detected three additional LSD derivatives from three paper...

Treatment of a Complex Personality Disorder Using Repeated Doses of LSD—A Case Report on Significant Improvements in the Absence of Acute Drug Effects

Frontiers in Psychiatry October 22, 2020 Felix Müller, Markus Mühlhauser, Friederike Holze et al. 31 citations

A 39-year-old female patient suffering from severe, treatment-resistant depression and other symptoms associated with a complex personality disorder was admitted to our open psychiatric ward for an experimental treatment with lysergic acid diethylamide (LSD). The substance was administered in repeated weekly and ascending doses. Curiously, there were no substantial acute subjective effects of...

Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study

European Neuropsychopharmacology October 17, 2020 Nadia R. P. W. Hutten, Natasha L. Mason, Patrick C. Dolder et al. 121 citations

There is a popular interest in microdosing with psychedelics such as LSD. This practice of using one-tenth of a full psychedelic dose according to a specific dosing schedule, anecdotally enhances mood and performance. Nonetheless, controlled research on the efficacy of microdosing is scarce. The main objective of the present dose-finding study was to determine the minimal dose of LSD needed to...

DOI: 10.1016/j.euroneuro.2020.10.002 (opens in new tab) Anxiety Mood Vigilance psychology Cognition +7

Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects

Neuropsychopharmacology October 15, 2020 Friederike Holze, Patrick Vizeli, Laura Ley et al. 243 citations

Abstract Growing interest has been seen in using lysergic acid diethylamide (LSD) in psychiatric research and therapy. However, no modern studies have evaluated subjective and autonomic effects of different and pharmaceutically well-defined doses of LSD. We used a double-blind, randomized, placebo-controlled, crossover design in 16 healthy subjects (eight women, eight men) who underwent six 25...

Acute subjective effects in LSD- and MDMA-assisted psychotherapy

Journal of Psychopharmacology October 8, 2020 Yasmin Schmid, Peter Gasser, Peter Oehen et al. 82 citations

Background: Lysergic acid diethylamide (LSD) and 3,4-methylenedioxymethamphetamine (MDMA) were used in psychotherapy in the 1960s–1980s, and are currently being re-investigated as treatments for several psychiatric disorders. In Switzerland, limited medical use of these substances is possible in patients not responding to other treatments (compassionate use). Methods: This study aimed to...